May 16 |
PainReform reports Q1 results
|
May 15 |
PainReform Provides Business Update for the First Quarter of 2024
|
May 8 |
PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com
|
Apr 18 |
PainReform Announces Closing of $4 Million Public Offering
|
Apr 16 |
PainReform prices its $4M offering at $0.80 apiece; shares fall
|
Apr 16 |
PainReform Announces Pricing of $4 Million Public Offering
|
Apr 9 |
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
|
Apr 9 |
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
|
Apr 2 |
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
|
Apr 2 |
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
|